Cleared Traditional

K251748 - MammoSTAR Biopsy Site Identifier (FDA 510(k) Clearance)

Class II General & Plastic Surgery device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2025
Decision
47d
Days
Class 2
Risk

K251748 is an FDA 510(k) clearance for the MammoSTAR Biopsy Site Identifier. Classified as Marker, Radiographic, Implantable (product code NEU), Class II - Special Controls.

Submitted by Carbon Medical Technologies, Inc. (St. Paul, US). The FDA issued a Cleared decision on July 23, 2025 after a review of 47 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4300 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Carbon Medical Technologies, Inc. devices

Submission Details

510(k) Number K251748 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 06, 2025
Decision Date July 23, 2025
Days to Decision 47 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
67d faster than avg
Panel avg: 114d · This submission: 47d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NEU Marker, Radiographic, Implantable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 878.4300
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General & Plastic Surgery devices follow this clearance model.

Regulatory Peers - NEU Marker, Radiographic, Implantable

All 109
Devices cleared under the same product code (NEU) and FDA review panel - the closest regulatory comparables to K251748.
HydroMARK™ Plus Breast Biopsy Site Marker (Dragonfly Shape)
K253761 · Devicor Medical Products, Inc. · Jan 2026
MOLLI 2 System
K253888 · Stryker Endoscopy · Dec 2025
SCOUT MD Surgical Guidance System
K252892 · Merit Medical Systems, Inc. · Dec 2025
VizMark Preloaded Tissue Marker Device (VM-0001)
K251989 · Breast-Med, Inc. · Dec 2025
UltraCor™ Twirl™ Breast Tissue Marker
K243642 · Bard Peripheral Vascular, Inc. · Mar 2025
SmartClip Secure Soft Tissue Marker
K233639 · Elucent Medical, Inc. · Dec 2024